Sudeep Pharma
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Sudeep Pharma is navigating a pivotal transition, with management emphasizing the long-term potential of its investments in battery-grade iron phosphate and the expansion of its Specialty Ingredients segment. The recent acquisition of Nutrition Supplies Services enhances its formulation capabilities and European market presence, positioning the company favorably amidst a diversifying global supply chain. However, near-term challenges persist, including European demand weakness and raw material cost inflation, which may temper revenue growth and margin stability. Vista's financial outlook reflects moderated revenue growth expectations, with stable margins anticipated as the company ramps up new projects. The balance sheet remains conservatively financed, supporting ongoing capital expenditures. Industry dynamics, particularly the shift towards Indian CDMOs and the favorable regulatory environment, bolster Sudeep's growth prospects. Over the next 12-24 months, key opportunities include the successful commissioning of the battery materials plant and the expansion of high-value nutrition products, while watchpoints include ongoing cost pressures and execution risks associated with new project rollouts
Why We Like This Stock
- Strategic investments in battery-grade iron phosphate are expected to drive long-term revenue growth
- Acquisition of Nutrition Supplies Services enhances formulation capabilities and market reach in Europe
- Strong customer engagement and initial orders for new products indicate robust demand potential
Things To Watch Out For
- Near-term challenges from European demand weakness and raw material cost inflation may impact margins
- Execution risks associated with new project rollouts could hinder growth expectations
- Transition year in FY28 may lead to low initial capacity utilization for new projects
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 459 | 502 | 642 | 689 | 778 |
| Profit Before Tax (Cr.) | 175 | 183 | 228 | 239 | 271 |
| PBT Margin | 38.1% | 36.4% | 3549.5% | 34.6% | 34.8% |
| Net Profit (Cr.) | 134 | 140 | 174 | 181 | 206 |
| Earnings Per Share | 11.9 | 12.4 | 15.4 | 16.1 | 18.2 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Prabhudas Liladhar | ▼ Reduce | 855 | 06-Aug-2026 |
Company Overview
Show Company Profile
Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in United States, Europe, United Kingdom, and Latin America. The company provides mineral salts, such as calcium, zinc, iron, potassium, magnesium, sodium, and copper to a range of health-focused applications; and calcium carbonate, which is used as an active pharmaceutical ingredient for various therapeutic applications. It also offers micronutrient premixes, encapsulated ingredients, liposomal and spray-dried formats, granulated minerals, and triturated blends to meet the needs across functional foods, dietary supplements, infant and clinical nutrition, fast-moving consumer goods, and convenience food formulations. In addition, the company is involved in manufacturing, developing, buying, selling, importing, exporting, trading, agency, testing, distributing, consigning, stocking, registering, packing, marketing, refining, and processing of pharmaceuticals, nutraceutical and nutrition products, food ingredients, mineral and vitamin blends, or premixes for infant, human and animal nutrition, and other chemical and healthcare products. Sudeep Pharma Limited was incorporated in 1989 and is based in Vadodara, India.